C.M. Bidwell & Associates’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

C.M. Bidwell & Associates’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-920	Closed	-$41K	–	556
2022 Q2	$41K	Sell	920 -20	-2%	-$919	0.03%	291
2022 Q1	$47K	Hold	940	–	–	0.03%	288
2021 Q4	$48K	Buy	+940	New	+$48.7K	0.03%	302
2018 Q4	–	Sell	-610	Closed	-$42K	–	476
2018 Q3	$42K	Buy	+610	New	+$46.2K	0.04%	243

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

C.M. Bidwell & Associates's EGRX Position: Q3 2022 in Review

C.M. Bidwell & Associates sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2022, closing a stake of 920 shares — an estimated $41K sold.

C.M. Bidwell & Associates first reported a position in EGRX in Q3 2018 and held it in 4 quarters. The position peaked at $48K in Q4 2021. 153 funds tracked by Wall St. Rank hold EGRX as of Q3 2022.

C.M. Bidwell & Associates reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
C.M. Bidwell & Associates sold 920 Eagle Pharmaceuticals, Inc. shares in Q3 2022, an estimated $41K.
C.M. Bidwell & Associates first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2018 and held it in 4 quarters.
C.M. Bidwell & Associates's Eagle Pharmaceuticals, Inc. position peaked at $48K in Q4 2021.
153 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2022.

Based on C.M. Bidwell & Associates's 13F filing for Q3 2022, filed 14 Nov 2022.